We are live on
!
Find out more
CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.67B
1-Year Est. Return
89%
This Fund
S&P 500
This Quarter
Est. Return
+16%
1 Year Est. Return
+89%
3 Year Est. Return
+264.17%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$324M
AUM Growth
+$28.5M
(+9.6%)
Cap. Flow
-$2.62M
Cap. Flow
% of AUM
-0.81%
Top 10 Holdings %
Top 10 Hldgs %
32.96%
Holding
465
New
18
Increased
159
Reduced
243
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard World Funds Extended Duration ETF
EDV
|
+$3.29M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
+$1.96M |
| 3 |
Apple
AAPL
|
+$1.92M |
| 4 |
Vaxcyte
PCVX
|
+$1.9M |
| 5 |
Meta Platforms (Facebook)
META
|
+$1.81M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iQIYI
IQ
|
+$5.11M |
| 2 |
Amazon
AMZN
|
+$4.12M |
| 3 |
Airbnb
ABNB
|
+$2.92M |
| 4 |
Analog Devices
ADI
|
+$2.79M |
| 5 |
KE Holdings
BEKE
|
+$2.12M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 41.8% |
| 2 | Consumer Discretionary | 21.38% |
| 3 | Healthcare | 19.26% |
| 4 | Communication Services | 6.74% |
| 5 | Financials | 4.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GRFS
301
Grifois
GRFS
$5.4B
| $13.9K | ﹤0.01% |
1,514
-10
| -0.7% | -$83 |
|
302
Procter & Gamble
PG
$335B
| $13.4K | ﹤0.01% |
88
+48
| +120% | +$7.24K |
|
303
Mirum Pharmaceuticals
MIRM
$6.04B
| $12.9K | ﹤0.01% |
498
-1
| -0.2% | -$27 |
|
304
Crinetics Pharmaceuticals
CRNX
$8.96B
| $12.8K | ﹤0.01% |
708
-23
| -3% | -$459 |
|
305
Adaptive Biotechnologies
ADPT
$4.02B
| $12.7K | ﹤0.01% |
1,891
-49
| -3% | -$364 |
|
306
Diageo
DEO
$52.2B
| $12.3K | ﹤0.01% |
+71
| New | +$12.7K |
|
307
Rhythm Pharmaceuticals
RYTM
$8.1B
| $12.3K | ﹤0.01% |
745
-18
| -2% | -$325 |
|
|
EQRX
308
DELISTED
EQRx, Inc. Common Stock
EQRX
| $11.9K | ﹤0.01% |
6,388
-232
| -4% | -$415 |
|
|
DAWN
309
DELISTED
Day One Biopharmaceuticals
DAWN
| $11.5K | ﹤0.01% |
964
-32
| -3% | -$418 |
|
310
Regenxbio
RGNX
$720M
| $11.4K | ﹤0.01% |
570
-19
| -3% | -$366 |
|
311
Cogent Biosciences
COGT
$6.76B
| $11K | ﹤0.01% |
930
-17
| -2% | -$195 |
|
312
Innoviva
INVA
$1.5B
| $10.9K | ﹤0.01% |
858
-65
| -7% | -$813 |
|
313
ADMA Biologics
ADMA
$2.19B
| $10.7K | ﹤0.01% |
2,913
-80
| -3% | -$297 |
|
314
Lyell Immunopharma
LYEL
$347M
| $10.4K | ﹤0.01% |
164
-5
| -3% | -$277 |
|
|
RNAM
315
DELISTED
Avidity Biosciences
RNAM
| $10.3K | ﹤0.01% |
928
-31
| -3% | -$389 |
|
316
Phathom Pharmaceuticals
PHAT
$742M
| $10.3K | ﹤0.01% |
717
+153
| +27% | +$1.76K |
|
317
Biomea Fusion
BMEA
$92.8M
| $10.2K | ﹤0.01% |
464
+66
| +17% | +$2.07K |
|
318
Arcturus Therapeutics
ARCT
$216M
| $9.98K | ﹤0.01% |
348
-12
| -3% | -$327 |
|
319
4D Molecular Therapeutics
FDMT
$621M
| $9.92K | ﹤0.01% |
549
+110
| +25% | +$2.02K |
|
320
Collegium Pharmaceutical
COLL
$834M
| $9.76K | ﹤0.01% |
454
-8
| -2% | -$182 |
|
321
Aclaris Therapeutics
ACRS
$860M
| $9.6K | ﹤0.01% |
926
+23
| +3% | +$208 |
|
322
Ardelyx
ARDX
$1.03B
| $9.53K | ﹤0.01% |
2,811
+121
| +4% | +$496 |
|
323
Allogene Therapeutics
ALLO
$714M
| $9.5K | ﹤0.01% |
1,912
-46
| -2% | -$249 |
|
324
Kura Oncology
KURA
$882M
| $9.49K | ﹤0.01% |
897
-31
| -3% | -$367 |
|
|
LKFT
325
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.83B
| $9.35K | ﹤0.01% |
230
+48
| +26% | +$1.96K |
|
Similar funds
HA
JPM
CPO
LCI
GWM
JIP
RMC
GACM
China Universal Asset Management Company's Q2 2023 Portfolio in Review
As of Q2 2023, China Universal Asset Management Company held 465 positions worth $324M, up 9.6% from $295M the previous quarter. Its ten largest holdings account for 33% of the portfolio.
China Universal Asset Management Company's Q2 2023 filing shows 18 new, 159 increased, 243 reduced and 13 closed positions. Its largest new stake was Vanguard World Funds Extended Duration ETF: 37,709 shares worth $3.28M. The largest sale was iQIYI, an estimated $5.11M.
By sector, the portfolio is most concentrated in Technology at 42% of assets, up from 38% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- China Universal Asset Management Company's largest Q2 2023 buy was Vanguard World Funds Extended Duration ETF: 37,709 shares worth $3.28M.
- China Universal Asset Management Company added most to Alnylam Pharmaceuticals in Q2 2023, an estimated $1.96M increase.
- China Universal Asset Management Company's biggest Q2 2023 reduction was iQIYI, cutting an estimated $5.11M.
- China Universal Asset Management Company fully exited Block Inc in Q2 2023, selling an estimated $1.35M.
- China Universal Asset Management Company's ten largest holdings make up 33% of its $324M portfolio in Q2 2023.
- China Universal Asset Management Company opened 18 new positions and closed 13 in Q2 2023.
- China Universal Asset Management Company's portfolio value rose 9.6% quarter-over-quarter to $324M.
Based on China Universal Asset Management Company's 13F filing for Q2 2023, filed 28 Jul 2023.